November 1, 2022
Life Sciences
  • Pfizer today announced promising topline results of a late-stage clinical trial for an experimental respiratory syncytial virus (RSV) vaccine. The vaccine would offer protection to infants from birth by vaccinating women while they’re still pregnant. The vaccine showed 82 percent efficacy against severe illness through the first 90 days of life and 69 percent through the first six months of life. Pfizer officials said they intend to submit for Food and Drug Administration (FDA) approval by the end of the year. White House COVID-19 adviser Ashish Jha told CNN he’s “hopeful” there could be an RSV vaccine available by next fall. (Articles here and here)